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Introduction.Diagnosticandtherapeuticguidelines,organizedassepsisbundles,havebeenshowntoimprovemortality,buttimely
and consistent implementation of these can be challenging. Our study examined the use of a screening tool and an early alert
system to improve bundle compliance and mortality. Methods. A screening tool was used to identify patients with severe sepsis or
septic shock and an overhead alert system known as Code SMART (Sepsis Management Alert Response Team) was activated at
the physician’s discretion. Data was collected for 6 months and compliance with bundle completion and mortality were compared
between the Code SMART and non-Code SMART groups. Results. Fifty eight patients were enrolled −34 Code SMART and 24
non-Code SMART. The Code SMART group achieved greater compliance with timely antibiotic administration (P<0.001),
lactate draw (P<0.001), and steroid use (P = 0.02). Raw survival and survival adjusted for age, leucopenia, and severity of illness
scores, were greater in the Code SMART group (P<0.05, P = 0.03, and P = 0.01). Conclusions. A screening tool and an alert
system can improve compliance with sepsis bundle elements and improve survival from severe sepsis and septic shock.
1.Introduction
Sepsis is one of the leading causes of mortality worldwide.
Over 750,000 hospitalizations occur in the United States
each year, with approximately 200,000 deaths [1]. Because
of such high mortality, guidelines known as Early Goal
Directed Therapy (EGDT) were developed to increase sepsis
awareness and direct therapy, thereby reducing mortality
[2]. The Surviving Sepsis Campaign subsequently classiﬁed
EGDT elements into a sepsis resuscitation bundle and a
sepsis management bundle [2]. These bundles direct speciﬁc
diagnostic and treatment strategies within designated time
frames. Better outcomes have been demonstrated when
compliance with bundle elements is high [3].
Consistent implementation of sepsis bundles has been
challenging. Noncompliance with sepsis bundles has been
demonstrated to increase in-hospital mortality for septic
patients, while compliance with the resuscitation bundle,
even if extended from the recommended time frame,
decreases mortality [4, 5]. We sought to develop an easy
to implement, low-cost system that would increase bundle
compliance and improve survival. This was initially devel-
oped as a quality improvement initiative and ultimately
became a standard of care in our facility. We hypothesized
that the use of an early alert system that brought an
interdisciplinary team rapidly to the patient’s bedside would
increase compliance with bundle elements and improve
survival for those presenting with severe sepsis or septic
shock.
2.MaterialsandMethods
2.1. Design, Overview, and Setting. This prospective cohort
study was performed in an Intensive Care Unit (ICU) in
a tertiary care, urban teaching hospital of 673 beds. This
ICU admits adult medical and surgical patients with the2 Critical Care Research and Practice
exception of patients who have undergone cardiothoracic
surgery. Our study protocol was reviewed and approved
by our Institutional Review Board (IRB) with a waiver of
informed consent as the study was deemed a performance
improvement intervention. The primary investigator super-
vised collection of study data during each patient’s ICU
admission.
2.2. Patients. All adult patients admitted to the ICU from
April 7th, 2009 through October 6th, 2009 were screened
for study entry. Patients with severe sepsis or septic shock
at the time of ICU admission (patients who developed
severe sepsis or septic shock while in the ICU were not
included), as deﬁned by Surviving Sepsis Campaign criteria
[2], were identiﬁed through the use of a written screening
tool based on standard deﬁnitions of these disorders [5].
This tool was utilized by Emergency Department (ED)
and Internal Medicine physicians to identify potential par-
ticipants. (Table 7—screening tool). All patients who met
criteria for severe sepsis or septic shock and all those on
whom a Code SMART was called were admitted to the
ICU. Additionally, we reviewed hospital admissions for the
ICD-9 codes corresponding to sepsis, septic shock, and
undiﬀerentiated shock to ensure that no patients during the
study period admitted to the “general ward” or other ICUs in
our institution.
2.3. Early Alert System Protocol. ED and ICU physicians,
nurses, respiratory care practitioner, and pharmacists were
educated regarding EGDT and sepsis bundles through
lectures and bedside teaching. Following these educational
sessions, a written screening tool was provided to staﬀ to
facilitate the identiﬁcation of appropriate patients. Patients
presenting to the ED or who demonstrated clinical dete-
rioration while admitted to the medical or surgical wards,
who met two or more criteria on the screening tool (thereby
demonstrating that they were likely to have severe sepsis
or septic shock) were intended to trigger an overhead alert
known as Code SMART (SMART = Sepsis Management
Alert Response Team). Such a trigger occurred based on
initial triage evaluation and took place within 30 minutes
of the patient’s arrival to the ED. Responders included an
(ICU) physician, (pulmonary and critical care medicine
fellow or attending physician), ICU nurse, respiratory care
practitioner, and pharmacist. Sepsis resuscitation and man-
agement bundle elements were implemented upon the Code
SMART team’s arrival at the bedside within 10 minutes
of the overhead alert call. This was accomplished using
a standardized order set to assess necessary diagnostic
and treatment information (see Figure 1—order set). Upon
arrival to the ICU, all patients with severe sepsis or septic
shock were managed according to a standardized protocol
also based on bundle elements (see Table 8—progress note).
Patients admitted with severe sepsis or septic shock, on
whom a Code SMART was not triggered, were then managed
by the same protocol (order set and progress note). However,
for Non-Code SMART patients, management was at the
discretion of the treating physician prior to ICU arrival.
Table 1: Patient characteristics between Code SMART and Non-
Code SMART Groups.
Code Smart Non-Code
Smart P
N = 34 N = 24
Mean (SD) Age (years) 70 (2.26) 61 (3.41) .03
Ethnicity
Caucasian 1 (3%) 3 (13%) .16
African American 28 (82%) 17 (71%) .31
Hispanic 3 (9%) 2 (8%) .95
Other 2 (6%) 2 (8%) .73
Gender (females) 15 (44%) 16 (67%) .42
Mean (SD) MEDS 11.44 (.94) 9.96 (1.13) .32
Sepsis
Urinary tract infection 10 (29%) 7 (29%) .80
Pneumonia 18 (53%) 8 (33%) .25
Cultures-positive
Blood 13 (38%) 8 (33%) .96
Urine 16 (47%) 7 (29%) .26
Shock present 25 (74%) 15 (63%) .38
Number of organs involved
0 2 (6%) 2 (8%) .72
1 8 (24%) 5 (21%) .81
2 8 (24%) 14 (50%) .01
3 10 (29%) 2 (8%) .05
4+ 6 (18%) 1 (4%) .13
Leucopenia 3 (9%) 2 (8%) .95
Table 2: Diﬀerence of means test for compliance with sepsis
bundles.
Observed Mean (SD)
Code SMART 34 6.50 (1.98)
Non-Code SMART 24 5.21 (2.28)
t = 2.7
∗
∗P = 0.1.
2.4. Data Documentation. For all patients included in this
study, the following demographic data was collected via the
electronicmedicalrecord:age,gender,andethnicity.Severity
of illness was assessed in all patients using MED scores [6–
8]. The origin of the admission to the ICU for each patient
was recorded (ED versus general medical-surgical ward).
Potential diﬀerences in the severity of illness between the
two groups were further assessed by evaluating the following
parameters: (1) site of sepsis, (2) rates of positive blood and
urine cultures, (3) the numbers of organs involved, (4) and
the presence or absence of shock.
The primary endpoint was compliance with each of the
ten individual resuscitation and management bundle el-
ements. A written case report form was completed by the
Code SMART team leader at the time of the Code SMART
and in the ensuing 24 hours. The secondary endpoint wasCritical Care Research and Practice 3
Patient label
Allergy: Patient weight: kg
(1) Admit patient to critical care and initiate these orders.
Sepsis:Presence or presumed presence of infection PLUS
Systemic Inﬂammatory Response Syndrome (SIRS)
2 or more of the following:
(1) Temp  >38◦C (100.3◦F) or <36◦C (96.8◦F)
Sepsis with ≥2 organ dysfunction
•
Hypoperfusion with lactic acidosis (lactate ≥4) •
Altered mental status •
Acute respiratory, renal, cardiac, or liver failure •
New-onset coagulopathy or thrombocytopenia
sepsis with MAP <65 or SBP <90, 
unresponsive to a crystalloid bolus dose 20–40 mL/kg IV
(2) Labs: obtain following labs STAT
•
Serum lactate •
Cortisol level •
Comprehensive metabolic panel (CMP) •
CBC •
PT/PTT/INR, ﬁbrinogen •
Blood cultures ×2 before initiating antibiotics •
Urinalysis and urine culture before initiating antibiotics •
Wound culture if appropriate, before giving antibiotics •
LFTs, CPK, Troponin, BNP •
Type and screen •
Other
After central line insertion, obtain the following labs and 
contact respiratory therapist to process
• Central Venous Blood Gas with CO-OXimeter NOW 
• Central Venous Blood Gas with CO-Oximeter in 4 hours 
(3) Diagnostic tests (Order based on patient’s presentation)
Indication:
Indication:
(4) Central line insertion and CVP monitoring.(Goal: achieve CVP 8–12 mmHg)
Insert A-line.
(5) IV Fluids: in the event of hypotension and/or serum lactate>4 mmol/L:
• If mean arterial pressure (MAP) less than 65 or systolic blood pressure (SBP) less than 90:
Check that apply.
Check that apply.
Bolus dose of Normal Saline IV mL (30 mL/kg) to be given over one hour.
mL (30 mL/kg) to be given over one hour. Bolus dose of lactated ringers IV
Bolus dose of Normal Saline IV mL (20 mL/kg) to be given over one hour.
mL (20 mL/kg) to be given over one hour. Bolus dose of lactated ringers IV
• After above dose, if CVP less than 8, then give another bolus dose of IV ﬂuids.
(6) GOAL: CVP 8–12 mmHg. 
In the event of persistent hypotension despite ﬂuid resuscitation (septic shock) and/or lactate>4 mmol/L:
Initiate vasopressor therapy: Check that apply.
Norepinephrine (Levophed) IV 4 mg/250 mL D5W. start at 2 mcg/min; titrate by 2 mcg/min every 5–10 minutes to MAP greater than or
equal to 65 or SBP greater than or equal to 90.
DOPAmine IV 400 mg/250 mL D5W.start at 2 mcg/kg/min; titrate by 2 mcg/kg/min every 5–10 minutes to MAP greater than or equal to  
65 or SBP greater than or equal to 90.
Vasopressin IV 100 units/100 mL NS. start at 2  units/hr and titrate to MAP greater than or equal to 65 or SBP greater than orequal to 90.
Phenylephrine (Neosynephrine) IV 20 mg/250 mL NS. start at 40 mcg/min and titrate to MAP greater than or equal to 65 or SBP greater
than or equal to 90.
Prescriber’s signature: Name:
Name:
Pager number: Date: Time:
Date: Time: RN’s Signature:
40189 Revised 11.2011 (ZYNX REVIEWED)
(7) Inotropic therapy   (consider in patients with cardiac decompensation)
DoBUTamine IV 500 mg/250 mL D5W. start at 2 mcg/kg/min; titrate by 2.5 mcg/kg/min every 30 mins until 
to 70%. discontinue if MAP <65 or HR >120.
• If DoBUTamine initiated, consider an Echocardiogram within 24 hours.
• If vasopressors initiated, obtain cortisol level and begin Hydrocortisone 100 mg IV q 8 hours
◦ If cortisol level <25 mcg/dL, continue Hydrocortisone 100 mg IV q 8 hours for 7 days.
◦ If cortisol level >25 mcg/dL, discontinue Hydrocortisone.
• If patient has received Prednisone 15 mg/day for more than 5 days in the last 3 months, then initiate Hydrocortisone 100 mg IV q 8 hours, 
regardless of the cortisol level.
Severe Sepsis and Septic Shock Orders
Severe Sepsis:
Septic Shock: (2) HR >90
(3) Resp. rate >20 or PaCO2 <32
(4) WBC >12,000 or <4,000
(goal: ScvO2 70%)
(goal: ScvO2 70%)
(8) Steroids
ScvO2 greater than or equal
ScvO2 greater than OR equal to 70% or ScvO2 greater than or equal to 65%
Figure 1: Continued.4 Critical Care Research and Practice
Patient label
 
Prescribers signature: Name:
Name:
Pager number: Date: Time:
Date: Time: RN’s Signature:
40189 Revised 11.2011 (ZYNX REVIEWED)
(9) Empiric antibiotics (give within 3 hrs of ED triage time and within 1 hr for non-ED admission).
Cefepime (maxipime) IV , ﬁrst dose STAT.
, ﬁrst dose STAT.
, ﬁrst dose STAT.
OR
OR
If patient has penicillin allergy: Aztreonam (Azactam) IV
(B) For coverage against gram-positive organisms:
Vancomycin IV
(A) For coverage against gram-negative organisms:
(C) For coverage against anaerobic organisms:
Clindamycin 600 mg IV q 8 hours, ﬁrst dose STAT.
Metronidazole (Flagyl) 500 mg IV q 8 hours, ﬁrst dose STAT.
(D) Other antibiotics:
Above antibiotic therapy recommended for empiric use only, reassess antibiotics after 48–72 hours based on culture and sensitivity results.
• If blood glucose greater than 150, then initiate and complete Glucose Control Protocol for ICU Patients.
(11) Drotrecogin alfa (Xigris):
• The use of drotrecogin alfa (Xigris) been considered in this patient.
• If patient meets the speciﬁed criteria, then initiate and complete the Xigris order form.
Severe Sepsis and Septic Shock Orders
Choose from below based on suspected or known source of infection:
(10) Fingerstick blood glucose testing q 2hours × 24hours. Notify MD if blood glucose is greater than 150 or less than 60.
Figure 1Critical Care Research and Practice 5
Table 3: Compliance with individual sepsis tasks.
Code SMART proportion
(S.D.)/n
Non-Code SMART proportion
(S.D.)/n t score P value
Antibiotics .91 (.03)/34 .54 (.10)/24 −4.57 <.001
Blood cultures .91 (.03)/34 .83 (.08)/24 −1.86 0.07
IV Fluids 0.71 (.08)/34 .50 (.10)/24 −1.59 0.11
Lactate .94 (.04)/34 .63.10/24 −3.24 <.001
CVP 1 (0)/18 .89 (.11)/9 −1.44 0.16
MV02 .50 (.11)/22 .38 (.18)/8 −0.59 0.56
Steroids .55 (.08)/34 .25 (.09)/24 −2.41 0.02
APC .61 (.08)/34 .41 (.10)/24 −1.52 0.14
Glucose .62 (.08)/34 .71 (.09)/24 0.71 0.48
IPP 1 (0)/7 1 (0)/12 n/a n/a
Table 4: Survival at discharge—Code SMART versus Non-Code
SMART.
Total patients Patients alive at discharge
Code SMART 34 31 (91%)
Non-Code SMART 24 17 (71%)
t =− 0.2.06
∗P<. 05.
Table 5: Model 1—logistic regression of mortality controlling for
+/− use of Code SMART, MEDS, and leucopenia.
Model 1 P value Odds ratios
Code SMART 2.11 (.96) 0.03 7.34
MEDS −.15 (.08) 0.06 0.83
Leucopenia −2.00 (1.35) 0.14 0.11
Constant 2.63 (.99) 0.01 —
N 58
χ2 13.81 0.00
Table 6: Model 2—Logistic regression of mortality controlling for
+/− use of Code SMART, MEDS, leucopenia, and age.
Model 2 P value Odds ratios
Code SMART 3.492635 (1.345015) 0.01 32.88
MEDS −.2171075 (.1181574) 0.07 0.80
Leucopenia −2.628451 (1.594963) 0.10 0.07
Age −.1090305 (.0494949) 0.03 0.89
Constant 10.68133 (5.680985) 0.06 —
N 58
χ2 23.94 0.00
mortality which was captured by the team leader at the time
of the patient’s discharge.
2.5.StatisticalAnalysis. Age,gender,ethnicity,andseverityof
illness as measured by MED scores were compared between
the participants who were in the Code SMART arm versus
those who were not part of Code SMART. An independent
samples t-test was used to determine if age and severity
of illness had a relationship with intervention arm, while
a chi-square analysis was used for gender and ethnicity.
Independent samples t-tests were also used to determine
any statistically signiﬁcant diﬀerences with respect to each
individual bundle element and survival at discharge and
intervention arm (Code SMART versus Non-Code SMART).
Finally, a logistic regression analysis was performed on
mortality as the outcome and the predictors of intervention
group (Code SMART versus Non-Code SMART), MED
scores, and leucopenia. A second logistic regression analysis
was performed by adding age to the ﬁrst model. All analyses
were performed using SPSS.
3. Results
Of 447 ICU admissions during the study period, 58 (7.7%)
were admitted with a primary diagnosis of severe sepsis or
septic shock and all were included in the study. Fifty-one
of these patients were admitted to the hospital from the ED
and of these, 32 triggered a Code SMART. The remaining 7
patients were admitted from general medical-surgical wards,
of which 2 were managed with a Code SMART.
As shown in Table 1, the two groups were similar dem-
ographically in terms of gender (χ2(1, N = 58) = .68, P =
.41), ethnicity (χ2(3, N = 58) = 2.23, P = .53), and MED
scores (P = .32). However, there was a statistically signiﬁcant
diﬀerence in age between the two groups, with the Code
SMARTpatientssigniﬁcantlybeingolderthantheNon-Code
SMART patients. The mean ages were 70 (SD = 2.3) and
61 (SD = 3.4) for the Code SMART and Non-Code SMART
patients,respectively.Furthermore,therewerenostatistically
signiﬁcant diﬀerences between the two groups with respect
to percentage of positive cultures, source of sepsis, presence
of absence of shock, and when zero, one, or more than four
organs were involved with the sepsis. There were statistically
more patients in the Code SMART group with two or three
organs involved in the disease process.
Ten sepsis bundles were compared collectively and indi-
vidually between the two groups. Collectively, compliance
with sepsis bundles was achieved more frequently in the6 Critical Care Research and Practice
Table 7: Evaluation for sepsis—screening Tool.
Instructions: Use this screening tool to screen patients for sepsis.
(1) Is the patient’s history suggestive of a new infection:
 no
 yes, if yes suspected source
 Pneumonia, empyema
 Urinary tract infection
 Acute abdominal infection
 Meningitis
 Skin/soft tissue infection
 Bone/joint infection
 Wound infection
 Bloodstream catheter infection
 Endocarditis
 Implantable device
 Other
(2) Are any two signs and symptoms of infection present AND new to the patient?
 Hyperthermia (>101◦F or 38.3◦C)
 Hypothermia (<96.8◦Fo r3 6 ◦C)
 Tachycardia (>90bpm)
 Tachypnea (>20bpm)
 Acutely altered mental status
 Leukocytosis (WBC count >12,000)
 Leukopenia (WBC count <4,000)
 >10% immature neutrophils
If t h ea n s w e ri sy e st ob o t hq u e s t i o n s1a n d2 ,suspicion of infection is present:
 Obtain: serum lactate, blood cultures, CBC with diﬀ, basic chemistry labs, bilirubin
 Pertinent diagnostic tests
(3) Are any of the following organ dysfunction criteria present AND acute:
 SBP < 90mmHg or MAP < 65mmHg
 SBP decrease >40mmHg from baseline
 Bilateral pulmonary inﬁltrates with a new (or increased) oxygen requirement to maintain SpO2 > 90%
 Creatinine > 2mg/dL or Urine Output < 0.5mL/kg/hr for more than 2 hours
 Bilirubin > 2mg/dL
 Platelet count <100,000
 Coagulopathy (INR > 1.5 or aPTT > 60secs)
 Serum lactate > 2mmol/L
If suspicion of infection is present AND organ dysfunction is present, the patient meets criteria for Severe sepsis.
If patient meets Severe sepsis criteria, AND has refractory hypotension (>60min AND/OR unresponsive to ﬂuid bolus of
20mL/kg), the patient meets criteria for Septic shock.
Initiateandcomplete the severesepsis protocol.
Code SMART group (P = .01; Table 2). Table 3 outlines
the speciﬁc elements that reached statistical signiﬁcance
with a greater compliance in the Code SMART population
includingtheadministrationofantibiotics(P<. 001),lactate
blood draw (P<. 001), and the use or documentation of the
consideration of steroid use. (P = .02) Blood culture draws
(P = .07) and intravenous ﬂuid administration (P = .11)
trended towards greater compliance in the Code SMART
group but did not reach statistical signiﬁcance.
Survival at discharge was compared between the two
study groups and was higher in the Code SMART group;
this diﬀerence achieved statistical signiﬁcance (P = .04;
see Table 4). When this data was adjusted for the use
of Code SMART, MED scores, and leucopenia, the Code
SMART patients enjoyed a sevenfold reduction in their risk
of mortality (Table 5). When mortality calculations were
furtheradjustedforthesefactorsplusage,thesurvivalbeneﬁt
was increased by a factor of greater than 32 (Table 6).Critical Care Research and Practice 7
Table 8: Sepsis patient daily progress note.
Date of Admission: Admitting Diagnosis:
Sepsis Information
Was sepsis present on admission (including ED stay)?: yes no
If no, date/time noted to be present:
Source of sepsis:
Evidence of infection (CXR, U/A, etc.):
Positive blood cultures and date:
End-organ damage:
Antibiotic and Other Treatment
Initial antibiotic therapy:
Current antibiotic therapy and start date:
Anticipated duration of antibiotic therapy:
Route of administration and need for long-term access:
Steroids considered/ Why given or not:
Xigris considered/Why given or not:
Please provide a brief summary of why the patient needs to remain in the hospital and cannot receive further treatment as an outpatient.
Signature/Title Date /Time
4. Discussion
This study demonstrates that an early alert system is an eﬀec-
tive tool for increasing compliance with sepsis resuscitation
and management bundle elements as its primary outcome.
Of the 10 bundle elements, the use of antibiotics, lactate
blood draw, and the use or consideration of steroids were
completed more consistently in the Code SMART group
compared to those treated without this alert system. The
most remarkable of these ﬁndings was the statistically sig-
niﬁcant diﬀerence between antibiotic administration timing
in the two groups, strongly favoring timely administration
in the Code SMART group. It appears that this diﬀerence is
not attributable to diagnostic uncertainty but due to failure
to utilize Code SMART.
Inspiratory plateau pressures <30cm H2Ow e r ea c h i e v e d
equally well in both groups. Although the ﬁnal seven
elements did not achieve statistical signiﬁcance, there was
a trend towards better compliance for six of the elements
in the Code SMART group. In addition, a signiﬁcant
reduction in unadjusted mortality in the Code SMART
patients was observed. After adjusting for leucopenia (an
independent risk factor for mortality from sepsis [9]) and
MED scores, the mortality beneﬁt in the Code SMART
becomes more signiﬁcant. Additional adjustment for age
(another independent risk factor for sepsis mortality [10]),
further implies this survival beneﬁt. The increased number
of organs involved in the sepsis process in the Code SMART
group would tend to bias against this group’s better overall
survival, which makes the observed mortality beneﬁt in the
Code SMART cohort a more robust ﬁnding.
Earlier antibiotic usage within the designated time frame
was the most statistically signiﬁcant in this study for the
Code SMART group. Not only has a combination of two
antibiotic therapies in the initial treatment of septic shock
shown to reduce mortality, but time of triage to antibiotic
administration has also been proven to decrease mortal-
ity [11–15]. Animal models have shown that a delay in
antibiotic administration following the onset of hypotension
is associated with an increase in inﬂammatory mediators
[16]. Prompt treatment is key, and reducing antimicrobial
burden by early antibiotic administration not only decreases
mortality in septic shock, butalsodecreasespressor/inotrope
free days, and ventilator days [12].
Increased lactate results from tissue hypoperfusion.
Decreased perfusion to tissue aﬀects mitochondrial oxidative
phosphorylation thereby shifting energy metabolism to
anaerobic glycolysis and the production of serum lactic
acid [17]. Measuring lactate levels may alert providers to
perfusion abnormalities that prompt therapeutic changes
that improve outcome. Therefore, interventions such as
Code SMART that improve the measurement of lactate may
facilitate these goal-directed interventions.
Early Goal-Directed Therapy and the Surviving Sepsis
Campaign demonstrated that early recognition and man-
agement of sepsis could save lives through implementation
of ten bundle elements. In addition, early alert system such
as Code STEMI for patients with ST-segment elevation
myocardial infarctions have demonstrated an improved rate
of survival with early recognition and implementation of
appropriate therapy. Our study demonstrates that such an
early intervention can be useful in severe sepsis and septic8 Critical Care Research and Practice
shock as well in that it increases compliance with bundle
elements and improves survival.
Afewpotentiallimitationsofthisstudydeservemention.
The ﬁrst limitation is our small sample size obtained over a
six-month study period in a single urban academic medical
center. As a follow-up study, a larger sample size from
multiplecenterswouldbedesirabletodeterminewhetherthe
observed positive trends in seven of the ten bundle elements
would reach statistical signiﬁcance. This data did not include
patients with cardiothoracic surgery and subsequent severe
sepsis or septic shock during the same hospitalization;
therefore, these results may not be applicable to this group.
A ﬁnal limitation was that Code SMART was not triggered
in all cases that met screening criteria during this ﬁrst six
months of the use of this tool. Potential barriers to triggering
a Code SMART in all patient may be the same as those faced
with regard to compliance to EGDT in the ED. Since Code
SMART has become established, it has become a standard of
care in our facility to call a Code SMART for every patient
meeting screening criteria.
In conclusion, severe sepsis and septic shock are medical
emergencies with an extremely high mortality rate. Code
SMART was shown to improve sepsis bundle compliance
in our institution as well as raw and adjusted mortality.
Code SMART functions as an early alert system that is easy
to implement, and essentially without cost, making it an
attractive tool for institutions to consider when meeting the
goals of early goal-directed therapy for severe sepsis and
septic shock.
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